Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Amgen
|
| gptkbp:acquisitionYear |
2013
|
| gptkbp:ceased_to_exist_as_independent_company |
2013
|
| gptkbp:collaboratedWith |
gptkb:Bayer
|
| gptkbp:developedBy |
gptkb:Nexavar_(sorafenib)
Kyprolis (carfilzomib) |
| gptkbp:focus |
cancer therapeutics
|
| gptkbp:founded |
1992
|
| gptkbp:founder |
gptkb:Frank_McCormick
|
| gptkbp:headquarters_location |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Onyx Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
gptkb:Nexavar
gptkb:Kyprolis |
| gptkbp:numberOfEmployees |
~500 (before acquisition)
|
| gptkbp:parentOrganization |
gptkb:Amgen
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
gptkb:ONXX
|
| gptkbp:website |
www.onyx-pharm.com
|
| gptkbp:bfsParent |
gptkb:Amgen
gptkb:sorafenib |
| gptkbp:bfsLayer |
6
|